{"summary": "Author argues EXEL is overvalued and about to be crushed because a Taiwanese generic of its key drug cabozantinib received full FDA approval while Wall Street has not yet connected the dots.", "reason": "The first idea provides a specific asset, a directional thesis, and a fundamental catalyst. The second idea is rejected because it is a watch/observation rather than an investment thesis.", "ideas": [{"symbol": "EXEL", "direction": "short", "thesis": "Author claims EXEL derives nearly all revenue (~$2B/yr) from cabozantinib (CABOMETYX) and that the FDA granted full approval to a Handa generic on 9/3, clearing the way for immediate US launch. EXEL allegedly withdrew its patent lawsuit against Handa on 8/31 and its FDA citizen petition failed, removing barriers to generic competition. The catalyst is Wall Street not yet pricing in the generic launch because the news was only published in Taiwan with no English coverage; the stock should get crushed once recognized. Main risk is that the market may already be aware or that generic launch timing/impact differs.", "thesis_short": "EXEL short on generic cabozantinib approval", "quote": "The key is: I think Wall St has genuinely not yet put two and two together, that this company's main source of revenue just got handed a major L by a cheaper generic, likely launching within days.", "confidence": 0.8, "sentiment": -0.8, "timeframe": "days to weeks"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}
This Reddit post, published September 08, 2026, features u/Biostatrat discussing EXEL. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Biostatrat · Tickers: EXEL